Shares of Baxter International Inc (NYSE:BAX) ended Thursday session in green amid volatile trading. The shares closed up +0.17 points or 0.37% at $46.07 with 5.15 million shares getting traded. Post opening the session at $45.83, the shares hit an intraday low of $45.75 and an intraday high of $46.38 and the price vacillated in this range throughout the day. The company has a market cap of $25.03 billion and the numbers of outstanding shares have been calculated to be 543.89 million shares.
Baxter International Inc (BAX) announced that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12 in New York. José (Joe) E. Almeida, chairman and chief executive officer is scheduled to present at 3:15 p.m. (CDT).
The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through December 12, 2016.
Shares of Genocea Biosciences Inc (NASDAQ:GNCA) ended Thursday session in green amid volatile trading. The shares closed up +0.22 points or 3.84% at $5.95 with 313,657.00 shares getting traded. Post opening the session at $5.78, the shares hit an intraday low of $5.71 and an intraday high of $6.09 and the price vacillated in this range throughout the day. The company has a market cap of $178.16 million and the numbers of outstanding shares have been calculated to be 178.16 million shares.
Genocea Biosciences Inc (GNCA) on Aug. 04, 2016 reported corporate highlights and financial results for the second quarter ended June 30, 2016.
“Full results from the Phase 2 dose optimization trial evaluating GEN-003, our immunotherapy for genital herpes, were showcased at ASM Microbe 2016 in June. The data show that a single course of treatment has significant and durable effects on both HSV-2 viral activity and genital herpes clinical disease for at least 12 months post dosing. Based on this clinical profile, we believe GEN-003 may offer benefits similar to a full year of daily administration of oral antivirals, giving us confidence in the potential for GEN-003 to become a cornerstone therapy for patients suffering with genital herpes,” said Chip Clark, president and chief executive officer of Genocea. “We are looking forward to reporting viral shedding and six-month clinical efficacy data from our ongoing Phase 2b study of GEN-003 in September and around the end of this year, respectively.”
Recent Business Highlights and Anticipated Milestones
GEN-003 – Immunotherapy for treatment of genital herpes in Phase 2 development. Greater than $1 billion potential revenue opportunity in U.S. alone
In June 2016, Genocea highlighted positive 12-month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes at the American Society for Microbiology (“ASM”) annual general meeting, ASM Microbe 2016. The study results, first announced in March 2016, demonstrate sustained and statistically significant reductions compared to baseline across multiple dose groups in the rate of viral shedding 12 months after treatment with GEN-003, as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was well tolerated by patients, with no serious adverse events related to the vaccine in the trial.